GSK vs. NVS
GSK (GSK plc) and NVS (Novartis AG) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, GSK returned 3.76%/yr vs 10.49%/yr for NVS. Their 0.50 correlation means they have sometimes moved together and sometimes differently.
Performance
GSK vs. NVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GSK achieves a 7.22% return, which is significantly lower than NVS's 16.71% return. Over the past 10 years, GSK has underperformed NVS with an annualized return of 3.76%, while NVS has yielded a comparatively higher 10.49% annualized return.
GSK
- 1D
- -0.73%
- 1M
- -3.67%
- 6M
- 1.90%
- YTD
- 7.22%
- 1Y
- 42.78%
- 3Y*
- 18.53%
- 5Y*
- 4.82%
- 10Y*
- 3.76%
- ALL TIME*
- 8.48%
NVS
- 1D
- -1.45%
- 1M
- -2.35%
- 6M
- 8.22%
- YTD
- 16.71%
- 1Y
- 39.55%
- 3Y*
- 18.79%
- 5Y*
- 15.30%
- 10Y*
- 10.49%
- ALL TIME*
- 9.10%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
GSK GSK plc | $276.89M | $237.83M | $206.74M |
NVS Novartis AG | $287.25M | $275.96M | $277.92M |
GSK vs. NVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK GSK plc | 7.22% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
NVS Novartis AG | 16.71% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
Correlation
The correlation between GSK and NVS is 0.69, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.69 |
Correlation (3Y) Balances recent behavior with more history. | 0.60 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.58 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.57 |
Correlation (All Time) Calculated using the full available price history since Nov 7, 1996 | 0.50 |
The correlation between GSK and NVS shifts across timeframes, from 0.50 (all time) to 0.69 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
GSK:
$103.56B
NVS:
$296.80B
GSK:
£2.36
NVS:
$6.63
GSK:
16.25
NVS:
23.56
GSK:
0.36
NVS:
1.59
GSK:
2.36
NVS:
5.40
GSK:
4.45
NVS:
7.19
GSK:
£33.25B
NVS:
$55.63B
GSK:
£24.35B
NVS:
$41.41B
GSK:
£10.68B
NVS:
$22.26B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK vs. NVS — Risk / Return Rank
GSK
NVS
GSK vs. NVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GSK plc (GSK) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK | NVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.25 | ||
| Sortino ratioReturn per unit of downside risk | -0.23 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.33 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 2.41 | 3.29 | -0.89 |
| Martin ratioReturn relative to average drawdown | 5.24 | 7.73 | -2.50 |
Loading charts...
Drawdowns
GSK vs. NVS - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.70%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for GSK and NVS.
Loading charts...
Drawdown Indicators
| GSK | NVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -55.70% | -42.10% | -13.60% |
Max Drawdown (1Y)Largest decline over 1 year | -18.53% | -12.65% | -5.88% |
Max Drawdown (3Y)Largest decline over 3 years | -28.46% | -19.95% | -8.51% |
Max Drawdown (5Y)Largest decline over 5 years | -50.10% | -20.42% | -29.68% |
Max Drawdown (10Y)Largest decline over 10 years | -50.10% | -26.03% | -24.07% |
Current DrawdownCurrent decline from peak | -14.05% | -4.58% | -9.47% |
Average DrawdownAverage peak-to-trough decline | -18.85% | -10.90% | -7.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.49% | 5.38% | +3.11% |
Volatility
GSK vs. NVS - Volatility Comparison
GSK plc (GSK) has a higher volatility of 8.74% compared to Novartis AG (NVS) at 7.89%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK | NVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.74% | 7.89% | +0.85% |
Volatility (6M)Calculated over the trailing 6-month period | 19.87% | 16.05% | +3.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.94% | 21.74% | +5.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.39% | 19.28% | +6.11% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.97% | 19.73% | +3.24% |
Dividends
GSK vs. NVS - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 3.47%, more than NVS's 3.06% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GSK plc | 3.47% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
NVS Novartis AG | 3.06% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
GSK vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between GSK plc and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK vs. NVS - Profitability Comparison
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, GSK plc reported a gross profit of 6.34B and revenue of 8.45B. Therefore, the gross margin over that period was 75.1%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Novartis AG reported a gross profit of 10.74B and revenue of 14.42B. Therefore, the gross margin over that period was 74.5%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, GSK plc reported an operating income of 2.41B and revenue of 8.45B, resulting in an operating margin of 28.5%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Novartis AG reported an operating income of 4.74B and revenue of 14.42B, resulting in an operating margin of 32.8%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, GSK plc reported a net income of 437.26M and revenue of 8.45B, resulting in a net margin of 5.2%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Novartis AG reported a net income of 3.27B and revenue of 14.42B, resulting in a net margin of 22.7%.
Frequently Asked Questions
GSK and NVS have a correlation of 0.69, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (8.74%) compared to NVS (7.89%). In terms of maximum drawdown, GSK dropped -55.70% vs NVS's -42.10%.
NVS currently has the higher Sharpe Ratio (1.93 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GSK and NVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer